Home
Aktis Oncology

Aktis Oncology Market Share Analysis for July 2026

Aktis is taking an innovative approach to anti-cancer therapies. Join a team focused on creating new precision therapies to put solid cancer into remission.

Industry: N/A

Domainaktisoncology.com

Year Founded2020

Employees51 - 200

Annual Revenue$5M - $10M

Aktis Oncology

Aktis Oncology (including company regionals)

aktisoncology.com

See more website traffic and engagement information

Aktis Oncology Revenue up to July 2026 is 5M - 10M

revenue generated by Aktis Oncology top domains

Aktis Oncology top domains revenue over 3 years

Revenue for Aktis Oncology top domains

aktisoncology.com5M - 10M

See more with Sales Intelligence

Total visits to Aktis Oncology's top domains

Understand Aktis Oncology market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

aktisoncology.com9.5K

See more with Sales Intelligence

Avg. visit duration in Aktis Oncology's top domains

Analyze Aktis Oncology engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

aktisoncology.com00:00:33

See more with Sales Intelligence

Avg. pageviews on Aktis Oncology's top domains

See how Aktis Oncology keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

aktisoncology.com2.40

See more with Sales Intelligence

Aktis Oncology top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Aktis Oncology

These are the website technologies, by industry, used by Aktis Oncology top domains

Email Services (2)

Microsoft Exchange Online

Mobile (2)

Meta Viewport

Widget (2)

Twemoji

Content Management System (1)

WordPress

More Technologies

3

See all

News & Signals from Aktis Oncology

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAktis Oncology, Inc. had revenue of $3.38M on Aug 13th '26.* Aktis Oncology met earnings expectations, reporting a quarterly loss of $0.44 per share while revenue of $3.38 million exceeded analyst estimates of $2.14 million.

NewsAktis Oncology, Inc. attended event BofA Securities Health Care Conference on May 6th '26.BOSTON, May 06, 2026 (GLOBE NEWSWIRE) - Aktis Oncology, Inc. (NASDAQ:AKTS) (the "Company"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the BofA Securities Health Care Conference in Las Vegas, Nevada.

NewsAktis Oncology, Inc. hired Glenn Gormley as independent Class I director on Apr 15th '26.Aktis Oncology appointed Glenn Gormley, MD, PhD, age 72, as an independent Class I director, effective April 15, 2026, with a term running until the 2027 annual stockholder meeting.